Senti Biosciences Holdings (SNTI) fair value: what the stock is really worth
As of Nov 19, 2026: fair value (intrinsic value) of Senti Biosciences Holdings stock $1.49, price $2.79, that is 46.6% below the price, quality 29 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Senti Biosciences Holdings
SNTI · USFar too expensive (fair value 47% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 20, 2026.
How to read this chart
60‑month range $2.79 – $3,379.20 · fair‑value band $1.12 – $1.86 · the $2.79 price screens above the $1.49 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 20, 2026.
Every Wednesday you see whether Senti Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases.
Show moreShow less
The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia.
In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells.
Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines.
The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026.
The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Stock analysis
Senti Biosciences Holdings (SNTI) currently trades at $2.79, while our estimate is $1.49, 47% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $1.12 (bear) to $1.86 (bull), the price of $2.79 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Senti Biosciences Holdings reported revenue of $22.0K in FY2025 versus $2.3M in FY2021, a compound −68.7%/yr. Reported net income was −$61.4M in FY2025.
Key figures
Market cap $8.0M · EPS (TTM) $-46.20 · Return on equity −466% · Return on assets (EBIT) −69.1% (5-year average) · Operating margin −62,343% · Free cash flow −$43.6M · Net debt $12.5M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (low confidence).
What moves the price
The share trades about 96% below its 52-week high and at its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −47%, SNTI screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, no officer or director bought or sold shares on the open market.
Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 19, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare Senti Biosciences Holdings with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Net margin by industry
- P/B ratio by industry
- Stock screener with 62 metrics
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $923.34 | $1,275.02 | +38% | vs SNTI |
| Vertex Pharmaceuticals Incorporated VRTX | $520.66 | $587.62 | +13% | vs SNTI |
| Samsung Biologics Co 207940 | ₩1,375,000 | ₩1,512,500 | +10% | vs SNTI |
| argenx SE ARGX | $942.04 | $908.40 | −4% | vs SNTI |
| CSL Limited CSL | A$197.29 | A$188.80 | −4% | vs SNTI |
| BeOne Medicines AG 6160 | HK$242.60 | HK$152.92 | −37% | vs SNTI |
| Moderna, Inc MRNA | $199.33 | $122.98 | −38% | vs SNTI |
| Revolution Medicines, Inc RVMD | $159.43 | $83.12 | −48% | vs SNTI |
| Celltrion, Inc 068270 | ₩215,000 | ₩74,574 | −65% | vs SNTI |
| Royalty Pharma plc RPRX | $67.72 | $19.01 | −72% | vs SNTI |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Senti Biosciences Holdings (SNTI) overvalued or undervalued?
What is the fair value of SNTI?
What is the quality score of SNTI?
What is the price target for Senti Biosciences Holdings (SNTI)?
What is the Senti Biosciences Holdings stock forecast for 2026?
What is the intrinsic value of Senti Biosciences Holdings (SNTI)?
Is Senti Biosciences Holdings stock overvalued or undervalued in 2026?
Is fair value the same as the market price of SNTI?
How much is Senti Biosciences Holdings worth?
What do the bullish and bearish scenarios say about SNTI?
How solid is the balance sheet of Senti Biosciences Holdings (SNTI)?
How far is SNTI from its 52-week high?
Which stocks are comparable to Senti Biosciences Holdings?
Is Senti Biosciences Holdings stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Senti Biosciences Holdings (SNTI)?
What should I pay attention to with Senti Biosciences Holdings right now?
Key figures of Senti Biosciences Holdings
How large is the market capitalisation of Senti Biosciences Holdings (SNTI)?
What are the earnings per share of Senti Biosciences Holdings (SNTI)?
What is the return on equity of Senti Biosciences Holdings (SNTI)?
What is the EBIT return on assets of Senti Biosciences Holdings (SNTI)?
What is the operating margin of Senti Biosciences Holdings (SNTI)?
How much free cash flow does Senti Biosciences Holdings (SNTI) generate?
How much net debt does Senti Biosciences Holdings (SNTI) carry?
Watch Senti Biosciences Holdings in the live analysis
One click puts Senti Biosciences Holdings on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.